References
- Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. 1998. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care. 21:1720–1725.
- Choi SJ, Hwang JM, Kim SI. 2003. A colorimetric microplate assay method for high throughput analysis of lipase activity. J Biochem Mol Biol. 36:417–420.
- de la Garza AL, Milagro FI, Boque N, Campio’n J, Marti’nez JA. 2011. Natural inhibitors of pancreatic lipase as new players in obesity treatment. Planta Med. 77:773–785.
- Isomaa B, Almgren P, Tuomi T, Forse'n B, Lahti K, Nisse’n M, Taskinen MR, Groop L. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24:683–689.
- Klein BE, Klein R, Lee KE. 2002. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. Diabetes Care. 25:1790–1794.
- Li B, Lu F, Nan H, Liu Y. 2012. Isolation and structural characterisation of okara polysaccharides. Molecules. 17:753–761.
- Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. 2010. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 56:1113–1132.
- Nishibori N, Kishibuchi R, Morita K. 2017. Soy pulp extract inhibits angiotensin I-converting enzyme (ACE) activity in vitro: Evidence for its potential hypertension-improving action. J Diet Suppl. 14:241–251.
- O'Toole DK. 1999. Characteristics and use of okara, the soybean residue from soy milk production. J Agric Food Chem. 47:363–371.
- Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, Lee WC, Kang MI, Yim HW, Yoon KH, et al. 2013. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 4:334–343.